As of November 6, 2026, 4 holders' latest Schedule 13D or 13G filings report owning 5% or more of Indivior Pharmaceuticals, Inc. The largest reported stake is BlackRock, Inc.'s, at 14.3%. 24 filings are on record since July 14, 2025 (Schedule 13G/A, January 8, 2026).
Who owns Indivior Pharmaceuticals, Inc.?
Sell to companies like Indivior Pharmaceuticals, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Millennium Management LLC · Sole voting: 0 · Shared voting: 6,343,651 · Sole dispositive: 0 · Shared dispositive: 6,343,651 · SCHEDULE 13G, 2026-09-30
- · Reporting person: Oaktree Value Opportunities Fund, L.P. · Sole voting: 0 · Shared voting: 385,037 · Sole dispositive: 0 · Shared dispositive: 385,037 · SCHEDULE 13D/A, 2026-08-13
- · Holder: Madison Avenue International LP · Percent: 3.5% · SCHEDULE 13G/A
- · Holder: Fuller & Thaler Asset Management, Inc. · Percent: 3.72% · SCHEDULE 13G/A
- · Holder: Vanguard Portfolio Management · Percent: 6.55% · SCHEDULE 13G
Indivior Pharmaceuticals, Inc. has 24 Schedule 13D or 13G filings on record since 2025-07-14. 4 holders' latest filing reports 5% or more of common stock, par value $0.001 per share. Each figure below is the holder's own, as filed, with the filing linked.
Layoffs on record: 1 filing or notice, latest 2025-10-30 (layoff filings and notices).
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| BlackRock, Inc. | 14.3% | 17,806,183 | SCHEDULE 13G/A, 2026-01-08 | 2025-12-31 |
| Vanguard Portfolio Management | 6.55% | 7,994,836 | SCHEDULE 13G, 2026-04-28 | 2026-03-31 |
| Millennium Management LLC | 5.4% | 6,343,651 | SCHEDULE 13G, 2026-09-30 | 2026-09-23 |
| Vanguard Capital Management | 5.35% | 6,523,720 | SCHEDULE 13G, 2026-04-27 | 2026-03-31 |
| Two Seas Capital LP | 4.98% | 6,211,854 | SCHEDULE 13D/A, 2025-12-23 | 2025-12-23 |
| Fuller & Thaler Asset Management, Inc. | 3.72% | 4,529,583 | SCHEDULE 13G/A, 2026-05-13 | 2026-03-31 |
| Deerfield Mgmt, L.P. | 3.7% | 4,614,498 | SCHEDULE 13G/A, 2025-11-13 | 2025-11-10 |
| Madison Avenue International LP | 3.5% | 4,315,162 | SCHEDULE 13G/A, 2026-05-15 | 2026-03-31 |
| The Goldman Sachs Group, Inc. | 2.9% | 3,592,431 | SCHEDULE 13G/A, 2026-02-12 | 2025-12-31 |
| Oaktree Capital Holdings, LLC | 0.76% | 909,053 | SCHEDULE 13D/A, 2026-08-13 | 2026-08-11 |
Holding shares or following this stake? See who's behind Indivior Pharmaceuticals, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Indivior Pharmaceuticals, Inc. and the records around it.
Indivior Pharmaceuticals, Inc. elsewhere on the record
- Leadership changes Nov 2026
- Layoff notices Oct 2025
- Who owns it
Companies that share a holder
- Oaktree Value Opportunities Fund, L.P. also filed stake reports on 4 other companies: TORM plc (Oct 2026), BRC Group Holdings, Inc. (May 2026)
- Madison Avenue International LP also filed stake reports on 11 other companies: Ultragenyx Pharmaceutical Inc. (Oct 2026), Graham Holdings Co (Aug 2026), STAAR SURGICAL CO (Aug 2026)
- Two Seas Capital LP also filed stake reports on 14 other companies: NEKTAR THERAPEUTICS (Sep 2026), Calumet, Inc. (Aug 2026), Quantum Corporation (Aug 2026)
Watch Indivior Pharmaceuticals, Inc.
Get an email when Indivior Pharmaceuticals, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Indivior Pharmaceuticals, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Indivior Pharmaceuticals, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Indivior Pharmaceuticals, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
26 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Millennium Management LLC | 0 | 6,343,651 | 0 | 6,343,651 | SCHEDULE 13G, 2026-09-30 |
| Millennium Group Management LLC | 0 | 6,343,651 | 0 | 6,343,651 | SCHEDULE 13G, 2026-09-30 |
| Israel A. Englander | 0 | 6,343,651 | 0 | 6,343,651 | SCHEDULE 13G, 2026-09-30 |
| Oaktree Value Opportunities Fund, L.P. | 0 | 385,037 | 0 | 385,037 | SCHEDULE 13D/A, 2026-08-13 |
| Oaktree London Liquid Value Opportunities Fund (VOF), L.P. | 0 | 180,169 | 0 | 180,169 | SCHEDULE 13D/A, 2026-08-13 |
| Oaktree Phoenix Investment Fund, L.P. | 0 | 51,271 | 0 | 51,271 | SCHEDULE 13D/A, 2026-08-13 |
| Oaktree Capital Management, L.P. | 0 | 292,576 | 0 | 292,576 | SCHEDULE 13D/A, 2026-08-13 |
| Oaktree Fund GP I, L.P. | 0 | 616,477 | 0 | 616,477 | SCHEDULE 13D/A, 2026-08-13 |
| Oaktree Capital Holdings, LLC | 0 | 909,053 | 0 | 909,053 | SCHEDULE 13D/A, 2026-08-13 |
The latest filing identifies Indivior Pharmaceuticals, Inc. by CUSIP 45579U109 and gives its principal executive office as 10710 Midlothian Turnpike, Suite 125, North Chesterfield, VA 23235 (SCHEDULE 13G, 2026-09-30).
Source of funds (Item 3)
Item 3 of the Schedule 13D is hereby amended and supplemented to insert the following at the end thereof: On various dates since the filing of Amendment No. 5, the Reporting Persons and certain of their affiliated funds and accounts engaged in open market purchases and sales of the Issuer's 0.625% Convertible Senior Notes due 2031 (the "Notes"), which are convertible into shares of Common Stock at an approximate conversion rate of $41.66 per share. The purchases of the Notes were pursuant to open market transactions, funded with working capital.Oaktree Capital Holdings, LLC, SCHEDULE 13D/A, 2026-08-13
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-07-14 | Two Seas Capital LP | 9.7% | SCHEDULE 13D/A |
| 2025-07-17 | BlackRock, Inc. | 6.8% | SCHEDULE 13G |
| 2025-07-29 | Two Seas Capital LP | 9.3% | SCHEDULE 13D/A |
| 2025-08-13 | The Goldman Sachs Group, Inc. | 7.8% | SCHEDULE 13G/A |
| 2025-09-05 | Two Seas Capital LP | 8.3% | SCHEDULE 13D/A |
| 2025-11-05 | Two Seas Capital LP | 7.4% | SCHEDULE 13D/A |
| 2025-11-12 | The Goldman Sachs Group, Inc. | 5.2% | SCHEDULE 13G/A |
| 2025-11-13 | Oaktree Capital Holdings, LLC | 7% | SCHEDULE 13D/A |
| 2025-11-13 | Deerfield Mgmt, L.P. | 3.7% | SCHEDULE 13G/A |
| 2025-12-10 | Two Seas Capital LP | 5.7% | SCHEDULE 13D/A |
| 2025-12-22 | Millennium Management LLC | 2% | SCHEDULE 13G |
| 2025-12-23 | Two Seas Capital LP | 4.98% | SCHEDULE 13D/A |
| 2025-12-30 | Oaktree Capital Holdings, LLC | 5.69% | SCHEDULE 13D/A |
| 2026-01-08 | BlackRock, Inc. | 14.3% | SCHEDULE 13G/A |
| 2026-02-12 | The Goldman Sachs Group, Inc. | 2.9% | SCHEDULE 13G/A |
| 2026-02-17 | Madison Avenue International LP | 5% | SCHEDULE 13G/A |
| 2026-02-17 | Fuller & Thaler Asset Management, Inc. | 5.1% | SCHEDULE 13G |
| 2026-03-23 | Millennium Management LLC | 3.8% | SCHEDULE 13G |
| 2026-04-27 | Vanguard Capital Management | 5.35% | SCHEDULE 13G |
| 2026-04-28 | Vanguard Portfolio Management | 6.55% | SCHEDULE 13G |
| 2026-05-13 | Fuller & Thaler Asset Management, Inc. | 3.72% | SCHEDULE 13G/A |
| 2026-05-15 | Madison Avenue International LP | 3.5% | SCHEDULE 13G/A |
| 2026-08-13 | Oaktree Capital Holdings, LLC | 0.76% | SCHEDULE 13D/A |
| 2026-09-30 | Millennium Management LLC | 5.4% | SCHEDULE 13G |
Questions about who owns Indivior Pharmaceuticals, Inc.
Who owns Indivior Pharmaceuticals, Inc.?
On this page, 4 holders' latest ownership filings report 5% or more of Indivior Pharmaceuticals, Inc.: BlackRock, Inc. (14.3%, Schedule 13G/A, filed 2026-01-08), Vanguard Portfolio Management (6.55%, Schedule 13G, filed 2026-04-28), Millennium Management LLC (5.4%, Schedule 13G, filed 2026-09-30) and Vanguard Capital Management (5.35%, Schedule 13G, filed 2026-04-27).
Who are the largest shareholders of Indivior Pharmaceuticals, Inc.?
By the share each holder's latest filing reports, the largest holders of Indivior Pharmaceuticals, Inc. on this page are BlackRock, Inc. (14.3%), Vanguard Portfolio Management (6.55%) and Millennium Management LLC (5.4%).
When did BlackRock, Inc. buy into Indivior Pharmaceuticals, Inc.?
The filings give report dates, not purchase dates. The earliest filing from BlackRock, Inc. on this page is the Schedule 13G, filed 2025-07-17, reporting 6.8%; its latest, Schedule 13G/A filed 2026-01-08, reports 14.3%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 24 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Indivior Pharmaceuticals, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| November 2, 2026 | Leadership change: Joseph Ciaffoni departs, Chief Executive Officer | — | Leadership changes | Source |
Tools for this story
Each opens in a new tab, filled in for Indivior Pharmaceuticals, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.